1. Home
  2. BBW vs IGMS Comparison

BBW vs IGMS Comparison

Compare BBW & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBW
  • IGMS
  • Stock Information
  • Founded
  • BBW 1997
  • IGMS 1993
  • Country
  • BBW United States
  • IGMS United States
  • Employees
  • BBW N/A
  • IGMS N/A
  • Industry
  • BBW Recreational Games/Products/Toys
  • IGMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBW Consumer Discretionary
  • IGMS Health Care
  • Exchange
  • BBW Nasdaq
  • IGMS Nasdaq
  • Market Cap
  • BBW 554.5M
  • IGMS 528.6M
  • IPO Year
  • BBW 2004
  • IGMS 2019
  • Fundamental
  • Price
  • BBW $43.43
  • IGMS $7.48
  • Analyst Decision
  • BBW Strong Buy
  • IGMS Buy
  • Analyst Count
  • BBW 3
  • IGMS 8
  • Target Price
  • BBW $54.33
  • IGMS $16.25
  • AVG Volume (30 Days)
  • BBW 337.9K
  • IGMS 213.0K
  • Earning Date
  • BBW 12-05-2024
  • IGMS 11-08-2024
  • Dividend Yield
  • BBW 1.84%
  • IGMS N/A
  • EPS Growth
  • BBW 8.16
  • IGMS N/A
  • EPS
  • BBW 3.79
  • IGMS N/A
  • Revenue
  • BBW $495,235,000.00
  • IGMS $2,918,000.00
  • Revenue This Year
  • BBW $2.56
  • IGMS $386.95
  • Revenue Next Year
  • BBW $2.52
  • IGMS N/A
  • P/E Ratio
  • BBW $11.48
  • IGMS N/A
  • Revenue Growth
  • BBW 2.76
  • IGMS 57.64
  • 52 Week Low
  • BBW $21.24
  • IGMS $6.17
  • 52 Week High
  • BBW $47.01
  • IGMS $22.50
  • Technical
  • Relative Strength Index (RSI)
  • BBW 61.16
  • IGMS 31.94
  • Support Level
  • BBW $40.93
  • IGMS $7.00
  • Resistance Level
  • BBW $43.09
  • IGMS $10.80
  • Average True Range (ATR)
  • BBW 2.35
  • IGMS 1.02
  • MACD
  • BBW 0.27
  • IGMS -0.10
  • Stochastic Oscillator
  • BBW 63.02
  • IGMS 10.39

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Share on Social Networks: